



Breakfast Symposium at AGW 2026

Treating to Target in Ulcerative Colitis: From Principle to Practice



Saturday 29 August, 2026



7:00–8:20 am (AWST)



Perth Convention and Exhibition Centre, Meeting Room 8

Join your colleagues for an expert-led breakfast symposium. As treatment goals evolve beyond symptom control towards disease clearance, this session will examine the clinical consequences of persistent inflammation and the rationale for earlier use of advanced therapy. Presentations will draw on real-world cases and Australian experience to provide practical guidance on when to escalate treatment.

Speakers



Associate Professor Jake Begun

Director of Gastroenterology,
Lead of IBD research,
Mater Hospital, Brisbane, QLD



Associate Professor Britt Christensen

Head of IBD Unit,
The Royal Melbourne Hospital,
Clinical Associate Professor,
University of Melbourne, VIC

Register now

Scan the QR code to register





Agenda

7.00am Breakfast available

7.20am Welcome and introduction – Chair A/Prof Jake Begun

7.25am **Start with the end in mind:**
The case for early advanced therapy and treatment selection with intent
A/Prof Jake Begun

7.45am **From symptom control to disease clearance:**
Setting and hitting deeper targets in Australian practice
A/Prof Britt Christensen

8.05am **Panel discussion**
Treating to target in ulcerative colitis: Putting it into practice
A/Prof Britt Christensen and A/Prof Jake Begun

8.20am Close

ENTYVIO® (vedolizumab) is indicated for the treatment of adult patients with moderate to severe ulcerative colitis or moderate to severe Crohn's disease, who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a TNF α antagonist.¹

Reference: 1. ENTYVIO Product Information.

PBS Information: Authority required. Refer to PBS for full details.

Please review Product Information before prescribing. Product Information is available from <https://www.takeda.com/en-au> or by scanning the QR code. Phone: 1800 012 612. Email: medinfoAPAC@takeda.com.



This meeting is subject to the Medicines Australia Code of Conduct Edition 20. This meeting is for Healthcare Professionals only. Personal information collected from you by Takeda when you register to attend this meeting will be used for communication about the meetings only. Your personal information will be treated in accordance with applicable laws and in accordance with Takeda policies. For more information you can check Takeda's privacy notice at www.takeda.com/privacy-notice/ or contact the Privacy Officer by e-mail at Privacyoffice@takeda.com or call +612 8019 4400.

Takeda Pharmaceuticals Australia Pty Limited, Sydney NSW 2000 Telephone: 1800 012 612. Email: medinfoAPAC@takeda.com. ABN 71 095 610 870. ENTYVIO® and the ENTYVIO Logo® are registered trademarks of Millennium Pharmaceuticals, Inc., a Takeda company. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited.

TAKE043c Date of preparation: July 2026. C-APROM/AU/ENTCD/0144